Principal Financial Group Inc C4 Therapeutics, Inc. Transaction History

Principal Financial Group Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$5.3 - $11.0 $8,029 - $16,665	-1,515 Reduced 10.27%	13,238 $108,000
Q4 2023 Feb 07, 2024	BUY	$1.18 - $6.03 $986 - $5,041	836 Added 6.01%	14,753 $83,000
Q2 2023 Aug 07, 2023	BUY	$2.75 - $3.77 $3,091 - $4,237	1,124 Added 8.79%	13,917 $38,000
Q1 2023 May 09, 2023	BUY	$3.1 - $9.02 $4,426 - $12,880	1,428 Added 12.56%	12,793 $40,000
Q4 2022 Feb 09, 2023	BUY	$5.42 - $10.24 $61,598 - $116,377	11,365 New	11,365 $67,000
Q1 2022 May 09, 2022	SELL	$19.99 - $33.23 $131,334 - $218,321	-6,570 Closed	0 $0
Q4 2021 Feb 09, 2022	SELL	$29.39 - $46.86 $45,143 - $71,976	-1,536 Reduced 18.95%	6,570 $212,000
Q3 2021 Nov 09, 2021	BUY	$35.91 - $50.5 $93,365 - $131,300	2,600 Added 47.22%	8,106 $362,000
Q2 2021 Aug 10, 2021	BUY	$30.39 - $42.18 $167,327 - $232,243	5,506 New	5,506 $208,000

130

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $208M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.